Epidermolysis bullosa

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Retrieved on: 
Monday, April 22, 2024
Carbon, Science, Corporation, Enzyme replacement therapy, FDA, AIR, License, International, RARE, Investment, Climate, Fabry disease, Climate change, CER, B Corporation (certification), CDP, Partnership, Empowerment, Alpha-mannosidosis, Parent, CARE, Chronic obstructive pulmonary disease, Environment, Culture, Benefit corporation, Patient, Science Based Targets initiative, Bronchiectasis, Acquisition, Caregiver, Epidermolysis bullosa, GHG, Place of birth, Health, Neonatology, Ethics, Asthma, RDS, Infant respiratory distress syndrome, Growth, Carbon Disclosure Project, COPD, Pharmaceutical industry

PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet.

Key Points: 
  • Chiesi's fixed triple formulation for the treatment of asthma and COPD (Chronic Obstructive Pulmonary Disease) achieved a 27% @CER growth.
  • Also, in 2023 it was introduced in China, presenting a pivotal opportunity for growth and expanding access to treatment for more patients.
  • In March 2023, Chiesi enriched its AIR portfolio thanks to the partnership with Affibody AB to develop and commercialize innovative treatments for respiratory diseases.
  • In November 2023, Chiesi signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel solution for bronchiectasis.

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Mutation, Epidermolysis bullosa, Skin cancer, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Protein, Life expectancy, Deformity, Blister, European, Skin, Collagen, COMP, Infection, Sponsor, European Commission, Safety, Unit, Marketing, COL7A1, Medicine, Pharmaceutical industry

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Key Points: 


Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham

Retrieved on: 
Wednesday, February 21, 2024
Commercial Building & Real Estate, Construction & Property, Technology, Consulting, Pharmaceutical, Oncology, Professional Services, Neurology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Health, Research, Senior, Culture, SCC, Epidermolysis bullosa, Pancreatic cancer, Sarcopenia, Cresa, Gold, Greater, Property, LEED, EB, Netherlands Architecture Institute, Lease administration, Knight Frank, Biology, Red Line (MBTA), Partnership, Therapy, Breast cancer, Multimedia, Capital market, Liver disease, Carcinoma, Type, Third, Lincoln, Quality of life, Government, GBM, Patient, Medicine, Glioblastoma, Business transaction management, Engineered wood

ft. of lab and office space at 300 Third Avenue in Waltham, Mass.

Key Points: 
  • ft. of lab and office space at 300 Third Avenue in Waltham, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20240221278304/en/
    300 Third Avenue in Waltham, Massachusetts.
  • 300 Third Avenue is a 143,533-sq.-ft. purpose-built life science building with four stories of laboratory space and 441 on-site parking spaces.
  • Lincoln Property Company (“Lincoln”) is one of the largest diversified real estate services companies with 35 offices across the United States the United Kingdom and Europe.

7th Annual Plunge for Elodie Set to Surpass $2.5 Million Raised for EB Research Partnership

Retrieved on: 
Thursday, February 29, 2024
Social media, Epidermolysis bullosa, Skin, Freezing, EB, Virtual, Disease, Movement, Research, Face

WELLESLEY, Mass., Feb. 29, 2024 /PRNewswire/ -- EB Research Partnership (EBRP) announces the 7th annual Plunge For Elodie scheduled for March 10 - April 27, 2024. Since its inception, the Plunge for Elodie has evolved from a small hometown fundraiser into a global movement, inviting participants to plunge into freezing waters to raise awareness and funds for the life-threatening rare genetic skin disorder, Epidermolysis Bullosa (EB). This year marks a groundbreaking year for the Plunge for Elodie with more than 20 events worldwide. The goal is to raise $500,000 in 2024 which would help the event's fundraising total surpass $2.5M raised for life-saving EB research since 2018. 

Key Points: 
  • WELLESLEY, Mass., Feb. 29, 2024 /PRNewswire/ -- EB Research Partnership (EBRP) announces the 7th annual Plunge For Elodie scheduled for March 10 - April 27, 2024.
  • This year marks a groundbreaking year for the Plunge for Elodie with more than 20 events worldwide.
  • The goal is to raise $500,000 in 2024 which would help the event's fundraising total surpass $2.5M raised for life-saving EB research since 2018.
  • The Plunge for Elodie was created by 10 childhood friends of Elodie's mom, EBRP Board Member Emily Kubik.

Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company

Retrieved on: 
Monday, February 5, 2024
Inflammation, DSM-IV codes, Hospital, Epidermolysis bullosa, Clinical trial, Dermatology, Cannabinoid, TSX, CBD, Ultra, CBG, Fine chemical

TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”).

Key Points: 
  • TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”).
  • Avicanna will be earning licensing fees associated to specific milestones and the parties have also agreed to specific minimum order quantities and efforts for Pharma to maintain the exclusivity.
  • The exclusive supply agreement is for the Company’s proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand across several medical cannabis platforms including MyMedi.ca.
  • Additionally, the two companies have entered into a separate right of first refusal agreement related to the Company’s SEDDS technology capsules for the same region.

BPGbio Appoints Ritesh Srivastava as General Counsel

Retrieved on: 
Monday, January 22, 2024
Technology, Biotechnology, Health, Neurology, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Research, Software, Infectious Diseases, Health Technology, Science, Clinical Trials, Pancreatic cancer, Carcinoma, General counsel, Type, Justice, Lieutenant commander, Spectrum Pharmaceuticals, Hematology, Breast cancer, Netherlands Architecture Institute, SCC, Parkinson's disease, Spectrum, Cancer, GBM, Glioblastoma, Sarcopenia, Srivastava, Therapy, Epidermolysis bullosa, EB, Liver disease, Growth, Medical imaging

BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.

Key Points: 
  • BPGbio, Inc ., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel.
  • Mr. Srivastava joins BPGbio from Spectrum Pharmaceuticals, a publicly traded biopharmaceutical company, where he held several leadership roles for over five years, including most recently as Global Compliance Officer.
  • At Spectrum, Mr. Srivastava provided leadership and counsel in all legal and compliance matters in acquiring, developing, and commercializing novel and targeted drug products in hematology and oncology.
  • “Ritesh Srivastava is a proven leader in the biopharma industry and a skilled corporate counsel,” said Niven R. Narain , Ph.D., CEO and President of BPGbio.

Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors

Retrieved on: 
Monday, November 13, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Carcinoma, Pancreatic cancer, Sarcopenia, Type, Parkinson's disease, MGM/UA, GBM, Liver disease, Breast cancer, News Corporation, EB, M.B.A, Therapy, Glioblastoma, General Securities Principal Exam, News, SCC, Epidermolysis bullosa, Columbia University, Netherlands Architecture Institute, Merrill (company), Management

BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.

Key Points: 
  • BPGbio, Inc ., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak , a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors , as an independent director.
  • “We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott , Executive Chairman of BPGbio.
  • He has served as a director of, and advisor to, several healthcare and technology companies.
  • He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).

EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research

Retrieved on: 
Tuesday, November 14, 2023
Major League Baseball, Chihuly Garden and Glass, Research, Yale University, Imagine, The Mayor, Entrepreneurship, Hope, Glass, ICON, Epidermolysis bullosa, Disease, Clinical trial, Learning, Patient, Former, FDA, Heart, EB, Humble (surname), Benaroya Hall, Stanford University, ICON PLC, MPH, MD, Doctor of Public Health, Parent, Digital health, AWS, Chief innovation officer, HSS, Pharmaceutical industry, Entertainment, Doctor of Philosophy

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Eddie Vedder played two intimate concerts in his hometown of Seattle at Benaroya Hall on October 23rd and 24th to bring support to a cause that is near to his heart – EB Research Partnership (EBRP). Alongside the emotional shows, EBRP hosted its first in-person Venture Into Cures Summit and Dinner.

Key Points: 
  • EB Research Partnership hosted the Venture Into Cures Summit alongside two Eddie Vedder shows in Seattle to support their mission of curing EB and other rare diseases.
  • EB Research Partnership and Jill and Eddie Vedder raised over $5M to benefit life-saving rare disease research.
  • Founded in 2010 by a group of dedicated parents, Jill Vedder, and Eddie Vedder of Pearl Jam, EB Research Partnership (EBRP) is the largest 501(c)(3) nonprofit funding research aimed at finding a cure for Epidermolysis Bullosa (EB).
  • We can make an impact for the millions out there battling a rare disease," said Jill Vedder, Co-Founder and Chairwoman at EBRP.

debra of America Raises $600,000 at Annual Benefit; Honors Trailblazers in Epidermolysis Bullosa Community

Retrieved on: 
Friday, November 10, 2023
Medicine, Health, Courage, Research, EBS, King County Superior Court, Therapy, Epidermolysis bullosa, Blister, Disease, Abrasion (medical), 34th Independent Spirit Awards, Patient, Genetic disorder, COL7A1, U.S. FDA, FDA, Epidermolysis bullosa dystrophica, EB, Partner, DEBRA, Conference, MD, Trauma, Survival, DEB, Junctional epidermolysis bullosa (medicine), Skin, Quality of life, Georgia Aquarium, Independent Spirit Awards, Government, Life, Legislation, Superior court, Policy, Pharmaceutical industry, Nursing

Funds raised help advance EB research initiatives and directly support families and individuals living with EB.

Key Points: 
  • Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
  • At the benefit, debra honored several EB trailblazers for their research and therapeutic contributions as well as individuals living with the disease.
  • Krystal Biotech was recognized for its work in developing VYJUVEK™ (beremagene geperpavec-svdt), the first FDA-approved treatment of Dystrophic Epidermolysis Bullosa (DEB).
  • Epidermolysis Bullosa is a rare genetic disorder characterized by fragile skin that easily blisters or forms painful sores from minor friction or trauma.